Respiratory
The Respiratory Department at St James’s hospital run a number of both investigator-led and industry centered drug trials in respiratory in conjunction with the CRF.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| GALACTIC-1 | A randomized, double-blind, multicentre, parallel, placebo-controlled study in patients with idiopathic pulmonary fibrosis (IPF) investigating the safety and efficacy of TD139, a dry powder, inhaled galectin-3 inhibitor | Clinical Trial | Galecto Biotech AB | Industry |
| Luster | A 52 week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma | Clinical Trial | Novartis Pharma UK Ltd | Commercial: Industry |
| MA39297 | An international trial to characterize the disease behaviour of idiopathic pulmonary fibrosis and interstitial lung disease during the peri-diagnostic period | Clinical Trial | F Hoffmann- La Roche Ltd | Commercial: Industry |
| BAL dccr | Airway Gene Expression Profiling and Immune Responses to Lung Disease (BAL) | Observational-non invasive | N/A | Non-commercial: Academic |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| Crystal | Crystal - A prospective, multicentre, 12 week, randomized open label study to evaluate the efficacy and safety of glycopyrronium (50 microgrms o.d.) or indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 micrograms o.d.) regarding symptoms and health status in patients with moderate chronic obstructive pulmonary disease (COPD) switching from treatment with any standard COPD regimen | Clinical tria | Novartis | Industry |
| Palladium | A multi-centre, randomised, 52 week treatment, double-blind, triple-dummy, parallel-group study to assess the efficacy and safety of QMF149 compared with mometason furoate in patients with asthma | Clinical trial | Novartis Pharma UK Ltd | Industry |